Leqvio FDA Approval
In the US, Leqvio® is positioned to meet the needs of 80% of
statin-treated ASCVD patients currently not at LDL-C goal
US ASCVD patient population¹
Diagnosed
Statin treated
At LDL-C goal²
4m
Non-statin therapy²
1m
20m
ך
-80%
30m
Leqvio® is uniquely positioned to
address unmet needs in ASCVD
A1 Adherence
Effective and sustained 4 LDL-C reduction with
two doses per year³, generally well-tolerated1
A2 Access
Medical benefit coverage for majority of
patients at launch
A3 Affordability
0 USD expected co-pay for 2/3 patients at launch
ASCVD - Atherosclerotic Cardiovascular Disease.
LDL-C - Low Density Lipoprotein Cholesterol. 1. Ray KK, et al. N Engl J Med. 2020;382(16): 1507-1519. 2. Non-statin lipid lowering therapies include ezetimibe and PCSK9i mAbs.
an initial dose, again at 3 months, and again every six months thereafter. 4. Across the 6-month dosing interval.
3. After
7
Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
V NOVARTIS | Reimagining MedicineView entire presentation